Sight Sciences (NASDAQ:SGHT) revised its revenue expectations for the year due to uncertainties surrounding the Medicare coverage for its products. Shares plummeted more than 46% intra-day today.

As a consequence of this uncertainty and a subsequent decrease in demand, the company now anticipates its full-year revenue to range between $80 million and $82 million. This is a decrease from their earlier projection of $89 million to $94 million.

Furthermore, for the third quarter, their revenue is estimated to be in the range of $19 million to $20 million, compared to the Street estimate of $23.7 million.

Sight Sciences plans to provide a comprehensive report on its third-quarter results in early November. Alongside this update, the company has announced the appointment of Matt Link as its Chief Commercial Officer.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

× ¿Cómo puedo ayudarte?